Art. -Nr.: HY-10181

Dasatinib

(Synonyms: BMS-354825)

175 Cited Publications

Kundenbewertung

Based on 175 publication(s) in Google Scholar

Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC₅₀s of <1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy, and can cross the blood-brain barrier.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.83%
CAS. Nr.: 302962-49-8
Formel: C₂₂H₂₆ClN₇O₂S
Molecular Weight:488.02

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Dasatinib Chemical Structure

CAS. Nr.: 302962-49-8

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (175)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

Bcr-Abl

1.0 nM (IC₅₀)

Src

0.5 nM (IC₅₀)

lck

0.4 nM (IC₅₀)

yes

0.5 nM (IC₅₀)

c-kit

5.0 nM (IC₅₀)

PDGFRβ

28 nM (IC₅₀)

p38

100 nM (IC₅₀)

Her1

180 nM (IC₅₀)

Her2

710 nM (IC₅₀)

FGFR-1

880 nM (IC₅₀)

MEK

1700 nM (IC₅₀)

Alle Bcr-Abl Isoform-spezifische Produkte anzeigen :

Abl
Bcr-Abl

Alle Src Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	8.7 μM Compound: 1, Dasatinib	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 25815152]
A549	IC₅₀	12.66 μM Compound: 3	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 23521020]
A549	IC₅₀	2.55 μM Compound: Dasatinib	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 38171149]
A549	IC₅₀	23.73 μM Compound: Dasatinib	Antiproliferative activity against human A549 cells after 72 hrs by CellTiter 96 aqueous one solution assay Antiproliferative activity against human A549 cells after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30562697]
A549	IC₅₀	8.2 μM Compound: Dasatinib, BMS-354825	Cytotoxicity against human A549 cells after 72 hrs by WST-8 assay Cytotoxicity against human A549 cells after 72 hrs by WST-8 assay	[PMID: 23567960]
A549	IC₅₀	8.37 μM Compound: Dasatinib	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 27155464]
ASPC1	IC₅₀	3.3 μM Compound: Dasatinib	Cytotoxicity against human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of cell growth Cytotoxicity against human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of cell growth	[PMID: 38848113]
B16-F10	IC₅₀	0.74 μM Compound: Dasatinib	Synergistic photodynamic antitumor activity against mouse B16-F10 cells assessed as inhibition of cell proliferation incubated for 48 hrs under 10 J/cm2 light irradiation at 660 nm in presence of chlorin e6 by CCK-8 assay Synergistic photodynamic antitumor activity against mouse B16-F10 cells assessed as inhibition of cell proliferation incubated for 48 hrs under 10 J/cm2 light irradiation at 660 nm in presence of chlorin e6 by CCK-8 assay	[PMID: 37690263]
B16-F10	IC₅₀	13.5 μM Compound: Dasatinib	Synergistic photodynamic antitumor activity against mouse B16-F10 cells assessed as inhibition of cell proliferation incubated for 48 hrs under dark condition in presence of chlorin e6 by CCK-8 assay Synergistic photodynamic antitumor activity against mouse B16-F10 cells assessed as inhibition of cell proliferation incubated for 48 hrs under dark condition in presence of chlorin e6 by CCK-8 assay	[PMID: 37690263]
B16-F10	IC₅₀	16.42 μM Compound: Dasatinib	Cytotoxicity against mouse B16-F10 cells incubated for 48 hrs under dark condition by CCK-8 assay Cytotoxicity against mouse B16-F10 cells incubated for 48 hrs under dark condition by CCK-8 assay	[PMID: 37690263]
BaF3	EC₅₀	>10 μM Compound: Dasatinib	Antiproliferative activity against wild type mouse BA/F3 cells incubated for 3 days by CCK8 assay Antiproliferative activity against wild type mouse BA/F3 cells incubated for 3 days by CCK8 assay	[PMID: 32657579]
BaF3	EC₅₀	>10 μM Compound: Dasatinib	Protac activity at Cereblon/BCR/ABL T315I mutant (unknown origin) expressed in mouse BaF3 cells assessed as reduction in BCR-ABL T315I mutant driven cell viability incubated for 3 days by CCK8 assay Protac activity at Cereblon/BCR/ABL T315I mutant (unknown origin) expressed in mouse BaF3 cells assessed as reduction in BCR-ABL T315I mutant driven cell viability incubated for 3 days by CCK8 assay	[PMID: 32657579]
BaF3	EC₅₀	>1000 nM Compound: Dasatinib	Inhibition of human BCR-ABL T315I mutant expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Inhibition of human BCR-ABL T315I mutant expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 27010810]
BaF3	EC₅₀	0.04 nM Compound: Dasatinib	Inhibition of human wild type BCR-ABL expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Inhibition of human wild type BCR-ABL expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 27010810]
BaF3	GI₅₀	<0.0003 μM Compound: Dasatinib	Inhibition of TEL-SRC (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of TEL-SRC (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	>10 μM Compound: Dasatinib	Antiproliferative activity against mouse BA/F3 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay Antiproliferative activity against mouse BA/F3 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	0.001 μM Compound: Dasatinib	Inhibition of BCR/ABL p210-Y253F mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of BCR/ABL p210-Y253F mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	0.001 μM Compound: Dasatinib	Inhibition of TEL-LCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of TEL-LCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	0.003 μM Compound: Dasatinib	Inhibition of BCR/ABL p210 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of BCR/ABL p210 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	0.003 μM Compound: Dasatinib	Inhibition of BCR/ABL p210-M351T mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of BCR/ABL p210-M351T mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	0.004 μM Compound: Dasatinib	Inhibition of BCR/ABL p210-H369P mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of BCR/ABL p210-H369P mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	0.005 μM Compound: Dasatinib	Inhibition of TEL-BLK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of TEL-BLK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	0.008 μM Compound: Dasatinib	Inhibition of BCR/ABL p210-Q252H mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of BCR/ABL p210-Q252H mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	0.01 μM Compound: Dasatinib	Inhibition of BCR/ABL p210-F317I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of BCR/ABL p210-F317I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	0.014 μM Compound: Dasatinib	Inhibition of BCR/ABL p210-F317L mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of BCR/ABL p210-F317L mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	0.017 μM Compound: Dasatinib	Inhibition of BCR/ABL p210-E255K mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of BCR/ABL p210-E255K mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	0.039 μM Compound: Dasatinib	Inhibition of TEL-HCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of TEL-HCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	3 μM Compound: Dasatinib	Inhibition of TEL-DDR1 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of TEL-DDR1 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	3 μM Compound: Dasatinib	Inhibition of TEL-DDR2 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of TEL-DDR2 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	GI₅₀	9.94 μM Compound: Dasatinib	Inhibition of BCR/ABL p210-T315I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay Inhibition of BCR/ABL p210-T315I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
BaF3	IC₅₀	>1 μM Compound: Dasatinib	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay	[PMID: 26195136]
BaF3	IC₅₀	>100 nM Compound: Dasatinib	Cytotoxicity against mouse BAF3 cells expressing BCR-ABL T315I mutant assessed as inhibition of cell growth measured after 48 hrs by trypan blue assay Cytotoxicity against mouse BAF3 cells expressing BCR-ABL T315I mutant assessed as inhibition of cell growth measured after 48 hrs by trypan blue assay	[PMID: 34011155]
BaF3	IC₅₀	>200 nM Compound: Chemical probe: BMS-354825	Cytotoxicity against mouse BaF3 cells assessed as reduction in cell proliferation incubated for 72 hrs by methane-thiosulfonate-based CellTiter96 viability analysis Cytotoxicity against mouse BaF3 cells assessed as reduction in cell proliferation incubated for 72 hrs by methane-thiosulfonate-based CellTiter96 viability analysis	[PMID: 15930265]
BaF3	IC₅₀	0.0002 μM Compound: 3	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL M351T mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL M351T mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	0.0009 μM Compound: 3	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F486S mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F486S mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	0.0013 μM Compound: 3	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E359V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E359V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	0.0019 μM Compound: 3	Cytotoxicity against mouse BA/F3 cells expressing wild type BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing wild type BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	0.0023 μM Compound: 3	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	0.0032 μM Compound: 3	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255K mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255K mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	0.0051 μM Compound: 3	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL G250E mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL G250E mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	0.008 μM Compound: 3	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Q252H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Q252H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	0.015 μM Compound: 3	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E355G mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E355G mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	0.017 μM Compound: 3	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253F mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253F mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	0.019 μM Compound: 3	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317L mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317L mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	0.023 μM Compound: 3	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	0.025 μM Compound: 3	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	0.029 μM Compound: 3	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL L248V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL L248V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	0.09 μM Compound: Dasatinib	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant after 72 hrs by MTT assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant after 72 hrs by MTT assay	[PMID: 26814890]
BaF3	IC₅₀	0.12 nM Compound: 3, BMS-354825	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M244V mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M244V mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	0.3 nM Compound: Dasatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 Q252H mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 Q252H mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	0.31 nM Compound: 3, BMS-354825	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396P mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396P mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	0.4 nM Compound: Dasatinib	Antiproliferative activity against native mouse BaF3 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against native mouse BaF3 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	0.51 nM Compound: 3, BMS-354825	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl G250E mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl G250E mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	0.58 nM Compound: 3, BMS-354825	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E355G mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E355G mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	0.58 nM Compound: 3, BMS-354825	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253F mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253F mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	0.7 nM Compound: Dasatinib	Cytotoxicity against mouse BAF3 cells expressing native BCR-ABL assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against mouse BAF3 cells expressing native BCR-ABL assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34011155]
BaF3	IC₅₀	0.83 nM Compound: 3, BMS-354825	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M351T mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M351T mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	1 nM Compound: Dasatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 Y253H mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 Y253H mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	1.1 nM Compound: Dasatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 M351T mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 M351T mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	1.2 nM Compound: Dasatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 H396P mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 H396P mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	1.29 nM Compound: 3, BMS-354825	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253H mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253H mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	1.71 nM Compound: 3, BMS-354825	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F486S mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F486S mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	1.72 nM Compound: 3, BMS-354825	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396R mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396R mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	1.91 nM Compound: 3, BMS-354825	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255V mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255V mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	1.94 nM Compound: 3, BMS-354825	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F359V mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F359V mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	1714 nM Compound: 3, BMS-354825	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	2 nM Compound: Dasatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 E255V mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 E255V mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	2 nM Compound: Dasatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 Y253F mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 Y253F mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	2.3 nM Compound: Dasatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 F317L mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 F317L mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	2.5 μM Compound: 3	Cytotoxicity against mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	2.7 nM Compound: Dasatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 F359C mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 F359C mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	2.8 nM Compound: Dasatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 G250E mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 G250E mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	3.6 μM Compound: 3	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	3.8 μM Compound: 3	Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL H396R mutant assessed as growth inhibition after 72 hrs by CCK-8 assay Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL H396R mutant assessed as growth inhibition after 72 hrs by CCK-8 assay	[PMID: 23301703]
BaF3	IC₅₀	3800 nM Compound: Dasatinib	Antiproliferative activity against parent mouse BaF3 cells assessed as inhibition of cell proliferation measured after 72 hrs in presence of IL-3 by MTT assay Antiproliferative activity against parent mouse BaF3 cells assessed as inhibition of cell proliferation measured after 72 hrs in presence of IL-3 by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	4.5 nM Compound: 3, BMS-354825	Antiproliferative activity against mouse BA/F3 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	5.72 nM Compound: 3, BMS-354825	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255K mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255K mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	5200 nM Compound: Dasatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 T315I mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 T315I mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	6.55 nM Compound: 3, BMS-354825	Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Q252H mutant after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Q252H mutant after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	65 nM Compound: Dasatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 T315A mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 T315A mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	6589 nM Compound: 3, BMS-354825	Antiproliferative activity against mouse BA/F3 cells after 72 hrs by CCK-8 assay Antiproliferative activity against mouse BA/F3 cells after 72 hrs by CCK-8 assay	[PMID: 23088644]
BaF3	IC₅₀	7.3 nM Compound: Dasatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 L248R mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 L248R mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	8 nM Compound: Dasatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 E255K mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 E255K mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BaF3	IC₅₀	8 nM Compound: Dasatinib	Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 V299L mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 V299L mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 21481795]
BXPC-3	EC₅₀	33 nM Compound: Dasatinib	Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 27010810]
CAKI-2	EC₅₀	55 nM Compound: Dasatinib	Antiproliferative activity against human Caki2 cells after 72 hrs by MTT assay Antiproliferative activity against human Caki2 cells after 72 hrs by MTT assay	[PMID: 27010810]
CHO	IC₅₀	81.1 μM Compound: dasatinib	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	[PMID: 23812503]
DLD-1	IC₅₀	4.6 μM Compound: Dasatinib, BMS-354825	Cytotoxicity against human DLD1 cells after 72 hrs by WST-8 assay Cytotoxicity against human DLD1 cells after 72 hrs by WST-8 assay	[PMID: 23567960]
DU-145	GI₅₀	0.0623 μM Compound: Dasatinib	Antiproliferative activity against human PRXF DU145 cells after 4 days by modified propidium iodide assay Antiproliferative activity against human PRXF DU145 cells after 4 days by modified propidium iodide assay	[PMID: 25076195]
DU-145	GI₅₀	0.16 μM Compound: Sprycel, NSC 723517	Cytotoxicity against human DU145 cells after 48 hrs by SRB assay Cytotoxicity against human DU145 cells after 48 hrs by SRB assay	[PMID: 24015327]
DU-145	IC₅₀	0.0623 μM Compound: Dasatinib	Cytotoxicity against human PRXF DU145 cells after 4 days by propidium iodide staining Cytotoxicity against human PRXF DU145 cells after 4 days by propidium iodide staining	[PMID: 23253074]
HCT-116	GI₅₀	3.7 μM Compound: Sprycel, NSC 723517	Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay	[PMID: 24015327]
HCT-116	IC₅₀	2.3 μM Compound: 3	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 23521020]
HCT-116	IC₅₀	3.58 μM Compound: Dasatinib	Antiproliferative activity against p53+/+ human HCT116 cells after 72 hrs by CellTiter 96 aqueous one solution assay Antiproliferative activity against p53+/+ human HCT116 cells after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30562697]
HCT-116	IC₅₀	5.23 μM Compound: Dasatinib	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 27155464]
HCT-116	IC₅₀	5.3 μM Compound: Dasatinib, BMS-354825	Cytotoxicity against human HCT116 cells after 72 hrs by WST-8 assay Cytotoxicity against human HCT116 cells after 72 hrs by WST-8 assay	[PMID: 23567960]
HEK293	EC₅₀	0.47 μM Compound: Dasatinib	Inhibition of recombinant Nanoluc-tagged p38alpha (unknown origin) expressed in HEK293 cells incubated for 2 to 3 mins by NanoBRET assay Inhibition of recombinant Nanoluc-tagged p38alpha (unknown origin) expressed in HEK293 cells incubated for 2 to 3 mins by NanoBRET assay	[PMID: 31520926]
HEK293	IC₅₀	14.3 μM Compound: 1, Dasatinib	Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay	[PMID: 25815152]
HEK293	IC₅₀	63 nM Compound: Dasatinib	Binding affinity to human full-length His-tagged Myt1 kinase expressed in HEK293 cells by TR-FRET based binding assay Binding affinity to human full-length His-tagged Myt1 kinase expressed in HEK293 cells by TR-FRET based binding assay	[PMID: 22770610]
HEL	GI₅₀	5.3 μM Compound: Dasatinib	Antiproliferative activity against human HEL cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay Antiproliferative activity against human HEL cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
Hep 3B2	GI₅₀	86 nM Compound: Dasatinib	Growth inhibition of human Hep3B cells after 3 days by MTT assay Growth inhibition of human Hep3B cells after 3 days by MTT assay	[PMID: 18979199]
HepG2	GI₅₀	>50000 nM Compound: Dasatinib	Growth inhibition of human HepG2 cells after 3 days by MTT assay Growth inhibition of human HepG2 cells after 3 days by MTT assay	[PMID: 18979199]
HepG2	IC₅₀	>5 μM Compound: dasatinib	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 25835317]
HepG2	IC₅₀	1.01 μM Compound: Dasatinib	Synergistic photodynamic antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs under 10 J/cm2 light irradiation at 660 nm in presence of chlorin e6 by CCK-8 assay Synergistic photodynamic antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs under 10 J/cm2 light irradiation at 660 nm in presence of chlorin e6 by CCK-8 assay	[PMID: 37690263]
HepG2	IC₅₀	18.2 μM Compound: Dasatinib	Cytotoxicity against human HepG2 cells incubated for 48 hrs under dark condition by CCK-8 assay Cytotoxicity against human HepG2 cells incubated for 48 hrs under dark condition by CCK-8 assay	[PMID: 37690263]
HepG2	IC₅₀	7.5 μM Compound: Dasatinib	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 27739679]
HepG2	IC₅₀	74.75 μM Compound: Dasatinib	Synergistic photodynamic antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs under dark condition in presence of chlorin e6 by CCK-8 assay Synergistic photodynamic antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs under dark condition in presence of chlorin e6 by CCK-8 assay	[PMID: 37690263]
HL-60	IC₅₀	14.97 μM Compound: Dasatinib	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
HMEC	GI₅₀	1.8 μM Compound: Sprycel, NSC 723517	Cytotoxicity against human HMEC after 72 hrs by WST1 assay Cytotoxicity against human HMEC after 72 hrs by WST1 assay	[PMID: 24015327]
Hs-578T	GI₅₀	0.03 μM Compound: Sprycel, NSC 723517	Cytotoxicity against human Hs578T cells after 48 hrs by SRB assay Cytotoxicity against human Hs578T cells after 48 hrs by SRB assay	[PMID: 24015327]
Huh-7	GI₅₀	1972 nM Compound: Dasatinib	Growth inhibition of human Huh-7 cells after 3 days by MTT assay Growth inhibition of human Huh-7 cells after 3 days by MTT assay	[PMID: 18979199]
JeKo-1	IC₅₀	1325 nM Compound: Dasatinib	Growth inhibition of human Jeko-1 cells incubated for 72 hrs Growth inhibition of human Jeko-1 cells incubated for 72 hrs	[PMID: 33479666]
Jurkat	IC₅₀	>1000 nM Compound: Dasatinib	Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34011155]
K562	CC₅₀	0.25 μM Compound: VI	Cytotoxicity against human K562 cells assessed as decrease in cell viability by MTT assay Cytotoxicity against human K562 cells assessed as decrease in cell viability by MTT assay	[PMID: 27474918]
K562	GI₅₀	<0.0003 μM Compound: Dasatinib	Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
K562	GI₅₀	0.0004 μM Compound: BMS-354825	Growth inhibition of human K562 cells measured after 48 hrs by alamarblue assay Growth inhibition of human K562 cells measured after 48 hrs by alamarblue assay	[PMID: 35944901]
K562	GI₅₀	9.7 μM Compound: BMS-354825	Growth inhibition of human K562 cells expressing BCR-ABL T315I mutant measured after 48 hrs by alamarblue assay Growth inhibition of human K562 cells expressing BCR-ABL T315I mutant measured after 48 hrs by alamarblue assay	[PMID: 35944901]
K562	IC₅₀	<1 nM Compound: 13, BMS-354825	Antiproliferative activity against human K562 cells after 72 hrs Antiproliferative activity against human K562 cells after 72 hrs	[PMID: 15615512]
K562	IC₅₀	0.00025 μM Compound: Dasatinib	Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26814890]
K562	IC₅₀	0.000638 μM Compound: 3	Antiproliferative activity against human K562 cells assessed as reduction in cell viability by measuring ATP level incubated for 3 days by Celltiter-Glo assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability by measuring ATP level incubated for 3 days by Celltiter-Glo assay	[PMID: 31303996]
K562	IC₅₀	0.0007 μM Compound: 3	Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay	[PMID: 23521020]
K562	IC₅₀	0.001 μM Compound: Dasatinib	Antiproliferative activity against human K562 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay Antiproliferative activity against human K562 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay	[PMID: 26195136]
K562	IC₅₀	0.001 μM Compound: Dasatinib	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
K562	IC₅₀	0.19 nM Compound: Dasatinib	Antiproliferative activity against human K562 cells incubated for 3 days by CCK8 assay Antiproliferative activity against human K562 cells incubated for 3 days by CCK8 assay	[PMID: 32657579]
K562	IC₅₀	0.2 nM Compound: Dasatinib	Cytotoxicity against human K562 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34011155]
K562	IC₅₀	0.45 μM Compound: BMS-354825	Cytotoxicity against human K562 cells expressing Bcr-Abl assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human K562 cells expressing Bcr-Abl assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26451772]
K562	IC₅₀	0.9 nM Compound: Dasatinib	Growth inhibition of human K562 cells incubated for 2 days by CCK8 assay Growth inhibition of human K562 cells incubated for 2 days by CCK8 assay	[PMID: 31539241]
K562	IC₅₀	0.9 nM Compound: Dasatinib	Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay	[PMID: 34217059]
K562	IC₅₀	1 nM Compound: 2, dasatinib,BMS-354825	Growth inhibition of human K562 cells after 48 hrs by [3H]thymidine uptake assay Growth inhibition of human K562 cells after 48 hrs by [3H]thymidine uptake assay	[PMID: 17956080]
K562	IC₅₀	11.9 μM Compound: Dasatinib, BMS-354825	Cytotoxicity against human K562 cells after 72 hrs by WST-8 assay Cytotoxicity against human K562 cells after 72 hrs by WST-8 assay	[PMID: 23567960]
K562	IC₅₀	11.95 μM Compound: Dasatinib	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 27155464]
K562	IC₅₀	12.83 μM Compound: BMS-354825, SPRYCEL	Cytotoxicity against human K562 cells after 72 hrs by WST-8 reagent based MTT assay Cytotoxicity against human K562 cells after 72 hrs by WST-8 reagent based MTT assay	[PMID: 22217877]
KM12	GI₅₀	7.44 μM Compound: Sprycel, NSC 723517	Cytotoxicity against human KM12 cells after 48 hrs by SRB assay Cytotoxicity against human KM12 cells after 48 hrs by SRB assay	[PMID: 24015327]
KU812 cell line	GI₅₀	<0.0003 μM Compound: Dasatinib	Antiproliferative activity against human KU812 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay Antiproliferative activity against human KU812 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
KU812 cell line	IC₅₀	0.1 nM Compound: Dasatinib	Cytotoxicity against human KU812 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human KU812 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34011155]
L02	IC₅₀	>40 μM Compound: Dasatinib	Cytotoxicity against human L02 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 27155464]
Malme-3M	GI₅₀	6.61 μM Compound: Sprycel, NSC 723517	Cytotoxicity against human MALME-3M cells after 48 hrs by SRB assay Cytotoxicity against human MALME-3M cells after 48 hrs by SRB assay	[PMID: 24015327]
Maver1	IC₅₀	1325 nM Compound: Dasatinib	Growth inhibition of human MAVER-1 cells incubated for 72 hrs Growth inhibition of human MAVER-1 cells incubated for 72 hrs	[PMID: 33479666]
MCF7	GI₅₀	8.32 μM Compound: Sprycel, NSC 723517	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 24015327]
MCF7	IC₅₀	>10 μM Compound: Dasatinib	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth	[PMID: 38848113]
MCF7	IC₅₀	1.11 μM Compound: Dasatinib	Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter 96 aqueous one solution assay Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30562697]
MCF7	IC₅₀	2.57 μM Compound: 3	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 23521020]
MCF7	IC₅₀	8.05 μM Compound: 1a	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25899332]
MDA-MB-231	EC₅₀	44 nM Compound: Dasatinib	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 27010810]
MDA-MB-231	GI₅₀	0.02 μM Compound: Sprycel, NSC 723517	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 24015327]
MDA-MB-231	IC₅₀	0.112 μM Compound: Dasatinib	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 27739679]
MDA-MB-231	IC₅₀	0.157 μM Compound: Dasatinib	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 38070430]
MDA-MB-231	IC₅₀	0.178 μM Compound: dasatinib	Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 25835317]
MDA-MB-231	IC₅₀	1.12 μM Compound: 1a	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25899332]
MDA-MB-231	IC₅₀	12 nM Compound: 13, BMS-354825	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs Antiproliferative activity against human MDA-MB-231 cells after 72 hrs	[PMID: 15615512]
MDA-MB-435	IC₅₀	5.147 μM Compound: Dasatinib	Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 27739679]
MDA-MB-435S	IC₅₀	3.9 μM Compound: 3	Antiproliferative activity against human MDA-MB-435S cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-435S cells after 72 hrs by MTT assay	[PMID: 23521020]
MEG-01	GI₅₀	<0.0003 μM Compound: Dasatinib	Antiproliferative activity against human MEG01 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay Antiproliferative activity against human MEG01 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
MOLM-14	GI₅₀	2.3 μM Compound: Dasatinib	Antiproliferative activity against human MOLM14 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay Antiproliferative activity against human MOLM14 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
MV4-11	GI₅₀	3.6 μM Compound: Dasatinib	Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
NCI-H1975	EC₅₀	173 nM Compound: Dasatinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay	[PMID: 27010810]
NCI-H1975	IC₅₀	1.26 μM Compound: Dasatinib	Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay	[PMID: 38171149]
NCI-H2286	IC₅₀	0.032 μM Compound: Dasatinib	Antiproliferative activity against human NCI-H2286 cells expressing DDR2 mutant after 72 hrs by alamar blue assay Antiproliferative activity against human NCI-H2286 cells expressing DDR2 mutant after 72 hrs by alamar blue assay	[PMID: 26191369]
NCI-H2286	IC₅₀	33.3 nM Compound: Dasatinib	Antiproliferative activity against human NCI-H2286 cells harboring DDR2 mutation after 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H2286 cells harboring DDR2 mutation after 72 hrs by CCK8 assay	[PMID: 30572178]
NCI-H23	IC₅₀	2.27 μM Compound: 3	Antiproliferative activity against human NCI-H23 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H23 cells after 72 hrs by MTT assay	[PMID: 23521020]
NCI-H460	IC₅₀	8.99 μM Compound: 3	Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay	[PMID: 23521020]
NCI-H661	IC₅₀	7.8 μM Compound: Dasatinib, BMS-354825	Cytotoxicity against human NCI-H661 cells after 72 hrs by WST-8 assay Cytotoxicity against human NCI-H661 cells after 72 hrs by WST-8 assay	[PMID: 23567960]
NHDF	IC₅₀	0.71 μM Compound: Dasatinib	Antiproliferative activity against human NHDF cells after 72 hrs by CellTiter 96 aqueous one solution assay Antiproliferative activity against human NHDF cells after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30562697]
PC-3	EC₅₀	232 nM Compound: Dasatinib	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 27010810]
PC-3	IC₅₀	9.4 nM Compound: 13, BMS-354825	Antiproliferative activity against human PC3 cells after 72 hrs Antiproliferative activity against human PC3 cells after 72 hrs	[PMID: 15615512]
PLC-PRF-5	GI₅₀	15 nM Compound: Dasatinib	Growth inhibition of human PLC-PRF-5 cells after 3 days by MTT assay Growth inhibition of human PLC-PRF-5 cells after 3 days by MTT assay	[PMID: 18979199]
SW-620	GI₅₀	8.43 μM Compound: Sprycel, NSC 723517	Cytotoxicity against human SW620 cells after 48 hrs by SRB assay Cytotoxicity against human SW620 cells after 48 hrs by SRB assay	[PMID: 24015327]
T47D	IC₅₀	0.9 μM Compound: 3	Antiproliferative activity against human T47D cells after 72 hrs by MTT assay Antiproliferative activity against human T47D cells after 72 hrs by MTT assay	[PMID: 23521020]
U-251	GI₅₀	2.81 μM Compound: Sprycel, NSC 723517	Cytotoxicity against human U251 cells after 48 hrs by SRB assay Cytotoxicity against human U251 cells after 48 hrs by SRB assay	[PMID: 24015327]
U-937	GI₅₀	>10 μM Compound: Dasatinib	Antiproliferative activity against human U937 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay Antiproliferative activity against human U937 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay	[PMID: 26789553]
U-937	IC₅₀	>1000 nM Compound: Dasatinib	Cytotoxicity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 34011155]
U-937	IC₅₀	≥ 100 nM Compound: dasatinib	Inhibition of LPS-induced Btk autophosphorylation on Tyr223 in human U937 cells at >= 100 nM after 1 hr Inhibition of LPS-induced Btk autophosphorylation on Tyr223 in human U937 cells at >= 100 nM after 1 hr	[PMID: 17684099]
U-937	IC₅₀	10.23 μM Compound: Dasatinib	Cytotoxicity against human U937 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human U937 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 27155464]
U-937	IC₅₀	12.2 μM Compound: Dasatinib, BMS-354825	Cytotoxicity against human U937 cells after 72 hrs by WST-8 assay Cytotoxicity against human U937 cells after 72 hrs by WST-8 assay	[PMID: 23567960]
U-937	IC₅₀	13.63 μM Compound: BMS-354825, SPRYCEL	Cytotoxicity against human U937 cells after 72 hrs by WST-8 reagent based MTT assay Cytotoxicity against human U937 cells after 72 hrs by WST-8 reagent based MTT assay	[PMID: 22217877]
U-937	IC₅₀	15.02 μM Compound: Dasatinib	Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay	[PMID: 36242991]
Vero C1008	EC₅₀	5.4 μM Compound: Dasatinib	Antiviral activity against MERS-CoV infected in african green monkey Vero E6 Antiviral activity against MERS-CoV infected in african green monkey Vero E6	[PMID: 37597435]
WiDr	IC₅₀	52 nM Compound: 13, BMS-354825	Antiproliferative activity against human WiDr cells after 72 hrs Antiproliferative activity against human WiDr cells after 72 hrs	[PMID: 15615512]

In Vitro

Dasatinib demonstrates significant activity against Bcr-Abl, Src, Lck, Yes, c-Kit, PDGFRβ, p38, Her1, Her2, FGFR-1, and MEK with IC₅₀s of <1.0, 0.50, 0.40, 0.50, 5.0, 28, 100, 180, 720, 880, and 1700 nM, respectively^[1].
Dasatinib shows antiproliferative activities aversus K562 chronic myelogenous leukemia (CML), PC3 human prostate tumor, MDA-MB-231 human breast tumor, and WiDr human colon tumor cell lines with IC₅₀s of <1.0 nM, 9.4 nM, 12 nM, and 52 nM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Dasatinib (5 mg/kg and 50 mg/kg, qd×10d, 5 on-2 off) possesses potent antitumor activity and a high safety margin in a K562 xenograft model of chronic myelogenous leukemia (CML), demonstrating complete tumor regressions and low toxicity at multiple dose levels^[1].
Dasatinib (10 mg/kg) has a pharmacokinetic profile appropriate for continued advancement into in vivo efficacy studies. Dasatinib (10 mg/kg) demonstrates favorable half-lives (t_1/2s) of 3.3 and 3.1 h for i.v. and oral, respectively. The oral bioavailability (F_po) in this study is 27%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Nude mice bearing K562 xenografts
Dosage:

5 mg/kg and 50 mg/kg
Administration:

Oral administration on a 5 day on and 2 day off schedule.
Result:

Showed partial tumor regressions after one treatment cycle and complete disappearance of the tumor mass by the end of drug treatment. No toxicity (animal deaths, lack of weight gain) was observed.

Animal Model:

Sprague-Dawley Rats
Dosage:

10 mg/kg (Pharmacokinetic Analysis)
Administration:

Oral and i.v.
Result:

C_max of 13.2 and 0.5 μM for i.v. and oral, respectively.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 302962-49-8
Appearance Solid
Molecular Weight 488.02
Formel C₂₂H₂₆ClN₇O₂S
Color White to off-white
SMILES

O=C(C1=CN=C(S1)NC2=NC(C)=NC(N3CCN(CC3)CCO)=C2)NC4=C(C=CC=C4Cl)C
Synonyms

BMS-354825
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (175)

All Cell Proliferation/Viability AssayIn Vivo Efficacy StudyWBELISAIFCell Migration/Invasion AssayRT-PCRCell Imaging/Staining

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Nature

Inhibitors supercharge kinase turnover through native proteolytic circuits. [Abstract]

2026 Jan;649(8098):1032-1041. PMID: 41299171
Cancer Cell

Gene context drift identifies drug targets to mitigate cancer treatment resistance. [Abstract]

2025 Jun 20:S1535-6108(25)00255-7. PMID: 40578362
Cancer Cell

Effective targeting of PDGFRA-altered high-grade glioma with avapritinib. [Abstract]

2025 Apr 14;43(4):740-756.e8. PMID: 40086436
Cell

Biosensors based on peptide exposure show single molecule conformations in live cells. [Abstract]

2021 Oct 28;184(22):5670-5685.e23. PMID: 34637702
J Hematol Oncol

Engineering a controllable and reversible switch for CAR-based cellular immunotherapies via a genetic code expansion system. [Abstract]

2024 Dec 18;17(1):122. PMID: 39696585
J Hematol Oncol

Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses. [Abstract]

2022 Apr 29;15(1):46. PMID: 35488312
J Hematol Oncol

Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance. [Abstract]

2018 Aug 29;11(1):109. PMID: 30157900

Dasatinib purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2018 Aug 29;11(1):109. [Abstract]

YSE450-R and EC109-R cells are treated with 200 nM BIBW 2992 alone or in combination with 100 nM Dasatinib for 48 h.

Dasatinib purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2018 Aug 29;11(1):109. [Abstract]

Resistant cells were treated with the indicated concentrations of afatinib in the presence or absence of 100 nM Dasatinib hydrochloride (Dasatinib) for 72 h, and CCK-8 assays were performed to assess cell viability.

Dasatinib purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2018 Aug 29;11(1):109. [Abstract]

Dasatinib hydrochloride (dasatinib; 15 mg/kg; daily for 21 days) showed anti-cancer activity in the xenograft growth of KYSE450-R and PDX03-R mice.

Dasatinib purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2018 Aug 29;11(1):109. [Abstract]

Dasatinib hydrochloride (dasatinib; 15 mg/kg; daily for 21 days) decreased the expression of phosphorylated S6 and ERK after afatinib combined with dasatinib treatment in xenografts growth of KYSE450-R and PDX03-R mice.

Dasatinib purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2018 Aug 29;11(1):109. [Abstract]

Dasatinib hydrochloride (Dasatinib; 20 μM; 2 h) suppressed silica particle (SP)-induced IL-1α and IL-1β release in BMDMs. Bone marrow-derived macrophages (BMDMs) were primed with lipopolysaccharide (LPS) (200 ng/mL) for 6 h. The cells were then treated with 20 µM of bosutinib, dasatinib, PD-161570, or PD-166285 and were stimulated or not stimulated with SPs (1,500 nm in diameter, 300 μg/mL) for 2 h. IL-1α and IL-1 beta (β) levels in the culture supernatants were measured using enzyme-linked immunosorbent assay (ELISA).

Dasatinib purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2018 Aug 29;11(1):109. [Abstract]

Dasatinib hydrochloride (Dasatinib; 20 μM; 4 h) suppressed SP-induced cell death accompanied by IL-1α and IL-1β release in phorbol 12-myristate 13-acetatetreated macrophage-like THP-1 cells. Phorbol 12-myristate 13-acetate-differentiated THP-1 cells were primed with LPS (50 ng/mL) for 16 h. The cells were then treated with dasatinib (20 µM) and were stimulated or not stimulated with SPs (1,500 nm in diameter, 500 μg/mL) for 4 h.

Dasatinib purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2018 Aug 29;11(1):109. [Abstract]

Dasatinib hydrochloride (Dasatinib; 20 μM; 2 h) suppressed silica particle (SP)-induced cell death. Bone marrow-derived macrophages (BMDMs) were primed with lipopolysaccharide (LPS) (200 ng/mL) for 6 h. The cells were then treated with 20 µM of bosutinib, dasatinib, PD-161570, or PD-166285 and were stimulated or not stimulated with SPs (1,500 nm in diameter, 300 μg/mL) for 2 h. The cell death rate was determined by measuring lactate dehydrogenase (LDH) activity in the culture supernatant.
Nat Immunol

Tissue-resident exhausted and memory CD8+ T cells have distinct ontogeny, function and role in disease. [Abstract]

2026 Jan;27(1):110-125. PMID: 41461986
Nat Biomed Eng

TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. [Abstract]

2018 Aug;2(8):578-588. PMID: 31015631
Immunity

p16High-expressing immune cells control disease tolerance as a defense and health span-extending strategy. [Abstract]

2026 Mar 26:S1074-7613(26)00083-X. PMID: 41895292
Immunity

Type 2 cytokine signaling in macrophages protects from cellular senescence and organismal aging. [Abstract]

2024 Mar 12;57(3):513-527.e6. PMID: 38262419
Cell Stem Cell

Senolytic-sensitive p16Ink4a+ fibroblasts in the tumor stroma rewire lung cancer metabolism and plasticity. [Abstract]

2025 Dec 4;32(12):1869-1885.e8. PMID: 41187746
Nat Aging

Spatiotemporal transcriptomic changes of human ovarian aging and the regulatory role of FOXP1. [Abstract]

2024 Apr;4(4):527-545. PMID: 38594460

Dasatinib purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]

Dasatinib (100 nM; 24 h). mRNA relative expression of CDKN2A, IL-6 and IL-8 in si-FOXP1 COV434 treated with fisetin (F), quercetin (Q) and Dasatinib (D).

Dasatinib purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]

Dasatinib (100 nM; 24 h). Immunofluorescence staining of Ki67 upon administration of fisetin (F), quercetin (Q) and Dasatinib (D) in COV434 with knockdown of FOXP1.

Dasatinib purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]

Dasatinib (100 nM; 24 h). Immunofluorescence staining of γH2AX upon administration of fisetin (F), quercetin (Q) and dasatinib (D) in COV434 with knockdown of FOXP1.

Dasatinib purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]

Fisetin (10 μM, 24 h), Quercetin (10 μM, 24 h), or Dasatinib (100 nM, 24 h) delayed FOXP1 gene silencing-induced cellular senescence in COV434 cells.
Nat Cell Biol

A neurodevelopmental epigenetic programme mediated by SMARCD3-DAB1-Reelin signalling is hijacked to promote medulloblastoma metastasis. [Abstract]

2023 Mar;25(3):493-507. PMID: 36849558

Dasatinib purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2023 Mar;25(3):493-507. [Abstract]

Dasatinib (50 nM; 24 or 48 h) significantly decreases MED8A and D458 cell migration.

Dasatinib purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2023 Mar;25(3):493-507. [Abstract]

Dasatinib (50 nM;24 h-48 h) significantly decreases MED8A cell migration.
Adv Funct Mater

27 January 2022.
Mol Cell

Endogenous YAP/TAZ partitioning in TEAD condensates orchestrates the Hippo response. [Abstract]

2025 Sep 18;85(18):3425-3442.e10. PMID: 40914169
Sci Immunol

Identification and characterization of dietary antigens in oral tolerance. [Abstract]

2026 Mar 6;11(117):eaeb4684. PMID: 41790933
Nat Commun

All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer. [Abstract]

2026 May 11. PMID: 42115161
Nat Commun

TAGAP instructs Th17 differentiation by bridging Dectin activation to EPHB2 signaling in innate antifungal response. [Abstract]

2020 Apr 20;11(1):1913. PMID: 32312989
Nat Commun

Alarmin-painted exosomes elicit persistent antitumor immunity in large established tumors in mice. [Abstract]

2020 Apr 14;11(1):1790. PMID: 32286296
J Am Chem Soc

Modulating the Binding Kinetics of Bruton's Tyrosine Kinase Inhibitors through Transition-State Effects. [Abstract]

2025 Aug 6;147(31):27876-27891. PMID: 40726426
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
J Clin Invest

Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression. [Abstract]

2023 Apr 3;133(7):e162324. PMID: 36795481
J Clin Invest

Cullin5 deficiency promotes small-cell lung cancer metastasis by stabilizing integrin β1. [Abstract]

2019 Mar 1;129(3):972-987. PMID: 30688657
Leukemia

Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia. [Abstract]

2020 Jun;34(6):1524-1539. PMID: 31848452
Leukemia

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. [Abstract]

2012 Oct;26(10):2233-44. PMID: 22469781

Dasatinib purchased from MedChemExpress. Usage Cited in: Leukemia. 2012 Oct;26(10):2233-44. [Abstract]

Drug combination effect on phosphorylation of AKT. Expression of phospho-AKT and total AKT in MOLM13 cells treated for 15 minutes with DMSO vehicle, PKC412 (2.5 nM), Dasatinib (165 nM), or a combination of both. Protein lysates are prepared from MOLM13 cells, and are analyzed via immunoblotting with antibodies to phospho-AKT and total AKT.
Biomaterials

Automated discovery of nanomaterials via drug aggregation induced emission. [Abstract]

2022 Oct:289:121800. PMID: 36166893
Sci Adv

FeaSion decodes the regulatory landscape and functional diversity of RNA polymerase II CTD phosphorylation. [Abstract]

2025 Nov 28;11(48):eadz2345. PMID: 41313762
Sci Adv

SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition. [Abstract]

2024 Dec 13;10(50):eadq4274. PMID: 39661665
Mol Ther

ROCK inhibition enhanced hepatocyte liver engraftment by retaining membrane CD59 and attenuating complement activation. [Abstract]

2023 Jun 7;31(6):1846-1856. PMID: 36860134
Biomark Res

PAQR5 drives the malignant progression and shapes the immunosuppressive microenvironment of hepatocellular carcinoma by activating the NF-κB signaling. [Abstract]

2025 May 7;13(1):70. PMID: 40336138
EBioMedicine

PPAR-γ suppresses macrophage senescence and allergic airway inflammation through controlling lipid metabolic pathways. [Abstract]

2026 Apr:126:106226. PMID: 41864062
MedComm (2020)

Integrated Multi-Omics Profiling to Characterize Molecular Subtypes and Reveal Potential Therapeutic Strategies for Colorectal Cancer. [Abstract]

2025 Dec 8;6(12):e70492. PMID: 41377767
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
J Immunother Cancer

Downregulation of RIG-I mediated by ITGB3/c-SRC/STAT3 signaling confers resistance to interferon-α-induced apoptosis in tumor-repopulating cells of melanoma. [Abstract]

2020 Mar;8(1):e000111. PMID: 32152220
Int J Biol Sci

Senescent renal tubular cells derived extracellular vesicles transported miR-20a and miR-21 induced macrophage-to-myofibroblast transition in renal fibrosis after ischemia reperfusion injury. [Abstract]

2025 Jan 6;21(3):940-954. PMID: 39897045
Cell Death Dis

Enhanced ferroptosis sensitivity promotes the formation of highly myopic cataract via the DDR2-Hippo pathway. [Abstract]

2025 Feb 3;16(1):64. PMID: 39900894
Cell Death Dis

Hippo signaling suppresses tumor cell metastasis via a Yki-Src42A positive feedback loop. [Abstract]

2021 Dec 3;12(12):1126. PMID: 34862372
Cell Commun Signal

Superbinder based phosphoproteomic landscape revealed PRKCD_pY313 mediates the activation of Src and p38 MAPK to promote TNBC progression. [Abstract]

2024 Feb 12;22(1):115. PMID: 38347536
J Pharm Anal

Synergistic effects of methyl 2-cyano-3,11-dioxo-18beta-olean-1,-12-dien-30-oate and erlotinib on erlotinib-resistant non-small cell lung cancer cells. [Abstract]

2021 Dec;11(6):799-807. PMID: 35028186
Int J Biol Macromol

Regulation of shelterin proteins TERF2IP and TRF2 by the MLL2-H3K4me3-p65 axis drives hyperglycemia-dependent endothelial senescence. [Abstract]

2025 Jun 4;318(Pt 1):144963. PMID: 40480577
Acta Pharmacol Sin

Adaptor protein CEMIP reduces the chemosensitivity of small cell lung cancer via activation of an SRC-YAP oncogenic module. [Abstract]

2024 Dec;45(12):2657-2671. PMID: 39043968
NPJ Precis Oncol

Clinical and preclinical insights into a novel MDM2::PDGFRA fusion in recurrent glioblastoma. [Abstract]

2025 Aug 16;9(1):289. PMID: 40819143
ACS Environ Au

Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]

2025 Aug 5;5(6):573-582. PMID: 41277996
Br J Pharmacol

Targeting the tyrosine kinase Src in endothelium attenuates inflammation and atherogenesis induced by disturbed flow. [Abstract]

2024 Aug 8. PMID: 39117589
Clin Sci

A novel epigenetic drug conjugating flavonoid and HDAC inhibitor confer suppression of acute myeloid leukemogenesis. [Abstract]

2021 Jul 30;135(14):1751-1765. PMID: 34282832
Biomed Pharmacother

Therapeutic strategy using novel RET/YES1 dual-target inhibitor in lung cancer. [Abstract]

2024 Feb:171:116124. PMID: 38198957
Biomed Pharmacother

Mitoquinone ameliorated airway inflammation by stabilizing β-catenin destruction complex in a steroid-insensitive asthma model. [Abstract]

2023 Jun:162:114680. PMID: 37060658
J Transl Med

Secretion of miRNA-326-3p by senescent adipose exacerbates myocardial metabolism in diabetic mice. [Abstract]

2022 Jun 21;20(1):278. PMID: 35729559
Cell Mol Gastroenterol Hepatol

Mannan-Binding Lectin via Interaction With Cell Surface Calreticulin Promotes Senescence of Activated Hepatic Stellate Cells to Limit Liver Fibrosis Progression. [Abstract]

2022 Apr 2;14(1):75-99. PMID: 35381393
Aging Cell

Morphofunctional Heterogeneity and Plasticity of Glioblastoma Cells Induced to Senescence by Temozolomide. [Abstract]

2026 Apr;25(4):e70477. PMID: 41963773
Cell Death Discov

Sympathetic nerve inhibition enhances calvarial bone repair via senescent macrophage-induced osteogenesis and angiogenesis. [Abstract]

2025 Dec 10;11(1):564. PMID: 41372112
Cell Rep

A generalized strategy to kill leukemic cells by targeting the regulatory systems governing mitochondrial membrane potential. [Abstract]

2025 Nov 25;44(11):116496. PMID: 41166305
J Med Chem

A Fast Method to Monitor Tyrosine Kinase Inhibitor Mechanisms. [Abstract]

2024 Nov 28;67(22):20571-20579. PMID: 39513680
Br J Cancer

PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib. [Abstract]

2023 Jan;128(1):148-159. PMID: 36319849
J Med Chem

Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors. [Abstract]

2021 Oct 14;64(19):14344-14357. PMID: 34547896
J Med Chem

Development of an In Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration. [Abstract]

2021 Mar 11;64(5):2725-2738. PMID: 33619967
J Anim Sci Biotechnol

Overexpression of Toll-like receptor 4 contributes to the internalization and elimination of Escherichia coli in sheep by enhancing caveolae-dependent endocytosis. [Abstract]

2021 May 10;12(1):63. PMID: 33966642
Oncogenesis

NEDD9 sustains hexokinase expression to promote glycolysis. [Abstract]

2022 Apr 11;11(1):15. PMID: 35410460
Commun Med (Lond)

Discovery of potent kinase inhibitors with improved pharmacokinetics and safety potentials through structural optimization of dasatinib. [Abstract]

2026 Apr 10. PMID: 41963539
J Pineal Res

MTNR1B loss promotes chordoma recurrence by abrogating melatonin-mediated β-catenin signaling repression. [Abstract]

2019 Sep;67(2):e12588. PMID: 31140197
JCI Insight

Neutrophil extracellular traps potentiate effector T cells via endothelial senescence in uveitis. [Abstract]

2025 Jan 23;10(2):e180248. PMID: 39846254
Cancer Cell Int

PRRG4 regulates mitochondrial function and promotes migratory behaviors of breast cancer cells through the Src-STAT3-POLG axis. [Abstract]

2023 Dec 16;23(1):323. PMID: 38102641
Cancer Cell Int

Construction of a prognostic model with histone modification-related genes and identification of potential drugs in pancreatic cancer. [Abstract]

2021 Jun 5;21(1):291. PMID: 34090418
Eur J Med Chem

ATTEC-mediated degradation of BCR-ABL in chronic myeloid leukemia cells. [Abstract]

2025 Dec 1:303:118430. PMID: 41344112
Clin Exp Ophthalmol

Novel Insight of Posterior Capsule Opacification: The Role of Lens Epithelial Cell Senescence. [Abstract]

2025 Jul 14. PMID: 40660668
Biochem Pharmacol

AMPK inhibition induces MCL1 mRNA destabilization via the p38 MAPK/miR-22/HuR axis in chronic myeloid leukemia cells. [Abstract]

2023 Mar:209:115442. PMID: 36720359
Mol Cancer Ther

Harnessing senolytics and PARP inhibition to expand the antitumor activity of CDK4/6 inhibitors in prostate cancer. [Abstract]

2025 Jul 2. PMID: 40601842
Chem Biol Interact

Digitoxin promotes apoptosis and inhibits proliferation and migration by reducing HIF-1α and STAT3 in KRAS mutant human colon cancer cells. [Abstract]

2022 Jan 5:351:109729. PMID: 34717917
J Chem Inf Model

Discovery of a Novel and Potent LCK Inhibitor for Leukemia Treatment via Deep Learning and Molecular Docking. [Abstract]

2024 Jun 24;64(12):4835-4849. PMID: 38847742
Cells

Lipophilic Statins Eliminate Senescent Endothelial Cells by inducing Anoikis-Related Cell Death. [Abstract]

2023 Dec 14;12(24):2836. PMID: 38132158
Life Sci

A protective role of ECSIT in chemotherapy-induced intestinal mucositis by maintaining Lgr5+ intestinal stem cells and gut homeostasis. [Abstract]

2026 Mar 15:389:124236. PMID: 41611204
Drug Des Devel Ther

Integrating Metabolomics, Histopathology, and Cardiac Marker Analysis to Assess Valsartan's Efficacy in Mitigating Dasatinib-Induced Cardiac Toxicity in Sprague-Dawley Rats. [Abstract]

2024 Dec 5:18:5641-5654. PMID: 39654603
Drug Des Devel Ther

Identification of Potential Therapeutics for Infantile Hemangioma via in silico Investigation and in vitro Validation. [Abstract]

2024 Sep 12:18:4065-4088. PMID: 39286286
Stem Cell Reports

Inhibition of Farnesyltransferase Potentiates NOTCH-Targeted Therapy against Glioblastoma Stem Cells. [Abstract]

2017 Dec 12;9(6):1948-1960. PMID: 29198824
Biomolecules

Targeting Cellular Senescence to Enhance Human Endometrial Stromal Cell Decidualization and Inhibit Their Migration. [Abstract]

2025 Jun 16;15(6):873. PMID: 40563513
Matrix Biol

Keratinocyte integrin α3β1 induces expression of the macrophage stimulating factor, CSF-1, through a YAP/TEAD-dependent mechanism. [Abstract]

2024 Mar:127:48-56. PMID: 38340968
Front Pharmacol

Dasatinib suppresses particulate-induced pyroptosis and acute lung inflammation. [Abstract]

2023 Aug 29:14:1250383. PMID: 37705538

Dasatinib purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2023 Aug 29:14:1250383. [Abstract]

Dasatinib hydrochloride (Dasatinib; 20 μM; 2 h) suppressed silica particle (SP)-induced cell death. Bone marrow-derived macrophages (BMDMs) were primed with lipopolysaccharide (LPS) (200 ng/mL) for 6 h. The cells were then treated with 20 µM of bosutinib, dasatinib, PD-161570, or PD-166285 and were stimulated or not stimulated with SPs (1,500 nm in diameter, 300 μg/mL) for 2 h. The cell death rate was determined by measuring lactate dehydrogenase (LDH) activity in the culture supernatant.
Biomolecules

Investigating the Effect of Tyrosine Kinase Inhibitors on the Interaction between Human Serum Albumin by Atomic Force Microscopy. [Abstract]

2022 Jun 11;12(6):819. PMID: 35740944
Front Pharmacol

Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1. [Abstract]

2021 Mar 8;12:644342. PMID: 33790797
RMD Open

RA-risk synovium exhibits DNA damage coupled with impaired DNA repair in fibroblasts. [Abstract]

2026 Jan 22;12(1):e005774. PMID: 41571322
Int Immunopharmacol

Osteopontin induces airway smooth muscle cells proliferation and migration by modulating FAK/Src/YAP axis. [Abstract]

2025 Dec 4:169:115886. PMID: 41349465
Bioorg Chem

Inhibition of FLT3-induced signalling in refractory acute myeloid leukaemia. [Abstract]

2025 Apr 5:160:108424. PMID: 40209351
Eur J Pharmacol

Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). [Abstract]

2021 Apr 15:897:173944. PMID: 33581133
Molecules

Facilitating Anti-Cancer Combinatorial Drug Discovery by Targeting Epistatic Disease Genes. [Abstract]

2018 Mar 23;23(4). pii: E736. PMID: 29570606
Artif Cells Nanomed Biotechnol

Study on tumour cell-derived hybrid exosomes as dasatinib nanocarriers for pancreatic cancer therapy. [Abstract]

2023 Dec;51(1):532-546. PMID: 37948136
Front Microbiol

Phosphorylation Status of Tyrosine 78 Residue Regulates the Nuclear Export and Ubiquitination of Influenza A Virus Nucleoprotein. [Abstract]

2019 Aug 7:10:1816. PMID: 31440228
Cancers (Basel)

Ras Pathway Activation and MEKi Resistance Scores Predict the Efficiency of MEKi and SRCi Combination to Induce Apoptosis in Colorectal Cancer. [Abstract]

2022 Mar 11;14(6):1451. PMID: 35326598
ACS Omega

ATP Promotes Oral Squamous Cell Carcinoma Cell Invasion and Migration by Activating the PI3K/AKT Pathway via the P2Y2-Src-EGFR Axis. [Abstract]

2022 Oct 26;7(44):39760-39771. PMID: 36385800
Front Cell Dev Biol

lncRNA Gm16410 Mediates PM2.5-Induced Macrophage Activation via PI3K/AKT Pathway. [Abstract]

2021 Mar 16:9:618045. PMID: 33796524
J Cell Mol Med

Inactivation of CDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage. [Abstract]

2026 Apr;30(7):e71101. PMID: 41896195
FEBS J

Catalytic activities of wild-type C. elegans DAF-2 kinase and dauer-associated mutants. [Abstract]

2024 Dec;291(24):5435-5454. PMID: 39428852
FASEB J

Biochemical characterization of the Drosophila insulin receptor kinase and longevity-associated mutants. [Abstract]

2024 Jan;38(1):e23355. PMID: 38071609
iScience

Targeting CD36 determines nicotine derivative NNK-induced lung adenocarcinoma carcinogenesis. [Abstract]

2023 Jul 27;26(8):107477. PMID: 37599821
Target Oncol

In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features. [Abstract]

2020 Oct;15(5):659-671. PMID: 32780298
J Biol Chem

The E3 ligase β-TRCP1 earmarks OTUD3 for destruction to fine-tune cGAS activation. [Abstract]

2026 Jun;302(6):111461. PMID: 41999888
Sci Rep

Src and β-catenin control a senescence-fibrotic phenotype in uterine fibroid cells. [Abstract]

2026 Jun 26. PMID: 42362678
Bioconjug Chem

Humoral Response to the Acetalated Dextran M2e Vaccine is Enhanced by Antigen Surface Conjugation. [Abstract]

2023 Aug 16;34(8):1447-1458. PMID: 37458383
Aging

Transient metabolic improvement in obese mice treated with navitoclax or dasatinib/quercetin. [Abstract]

2020 Jun 25;12(12):11337-11348. PMID: 32584785
Clin Exp Immunol

Senolytic treatment to rescue hallmarks of senescence in lymph node fibroblasts from patients with rheumatoid arthritis: Implications for premature aging and potential therapeutic intervention in early rheumatoid arthritis. [Abstract]

2025 May 8:uxaf029. PMID: 40336246
J Virol

Vascular endothelial growth factor receptor 2 as a potential host target for the inhibition of enterovirus replication. [Abstract]

2024 Sep 17:e0112924. PMID: 39287389
Bioengineering (Basel)

Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]

2025 Oct 19;12(10):1121. PMID: 41155119
Cell Signal

Effects of heterologous kinase domains on growth factor receptor specificity. [Abstract]

2024 Oct:122:111307. PMID: 39048037
ACS Pharmacol Transl Sci

Fluorescent Detection of Peroxynitrite Produced by Myeloid-Derived Suppressor Cells in Cancer and Inhibition by Dasatinib. [Abstract]

2023 May 2;6(5):738-747. PMID: 37200815
J Immunol Res

Combined Effects of 2-Methoxyestradiol (Hypoxia-Inducible Factor 1 α Inhibitor) and Dasatinib (A Second-Generation Tyrosine Kinase Inhibitor) on Chronic Myelocytic Leukemia Cells. [Abstract]

2022 Apr 28;2022:6324326. PMID: 35528614
Mol Hum Reprod

Down-regulation of IGFBP2 mediates endometrial epithelial cells senescence in thin endometrium. [Abstract]

2025 Jul 3;31(3):gaaf032. PMID: 40700608
Med Oncol

Src inhibitor dasatinib sensitized gastric cancer cells to cisplatin. [Abstract]

2022 Dec 16;40(1):49. PMID: 36525117
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
J Prosthodont Res

Cellular senescence of RANKL+ osteoblasts and Th17 cells in severe periodontitis with occlusal trauma. [Abstract]

2025 Feb 11. PMID: 39938897
PLoS Negl Trop Dis

Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]

2019 Aug 20;13(8):e0007681. PMID: 31430351
Analyst

Quantification of olaparib in human liver microsomes using an ultra-fast UPLC-MS/MS quantitative approach: in vitro and in silico metabolic stability assessment. [Abstract]

2026 Mar 5. PMID: 41784206
Int J Med Sci

Naringenin Mitigates Dasatinib-Induced Kidney Damage by Modulating Antioxidant Defense, Inflammation, and Apoptosis Pathways. [Abstract]

2025 Jan 1;22(1):110-120. PMID: 39744177
Hum Exp Toxicol

Hydroxychloroquine ameliorates dasatinib-induced liver injury via decrease in hepatic lymphocytes infiltration. [Abstract]

2023 Jan-Dec:42:9603271231188492. PMID: 37431997
Cancer Med

Focal Adhesion Kinase Intersects With the BRD4-MYC Axis and YAP1 to Drive Tumor Cell Growth, Phenotypic Plasticity, Stemness, and Metastatic Potential in Colorectal Cancer. [Abstract]

2025 Sep;14(18):e71227. PMID: 40959971
Diseases

Examining the Effects of Dasatinib, Sorafenib, and Nilotinib on Vascular Smooth Muscle Cells: Insights into Proliferation, Migration, and Gene Expression Dynamics. [Abstract]

2023 Oct 23;11(4):147. PMID: 37873791
Gerontology

Senolytics Cocktail Dasatinib and Quercetin Alleviate Human Umbilical Vein Endothelial Cell Senescence via the TRAF6-MAPK-NF-κB Axis in a YTHDF2-Dependent Manner. [Abstract]

2022;68(8):920-934. PMID: 35468611
Breast Cancer Res Treat

Molecular determinants of drug response in TNBC cell lines. [Abstract]

2020 Jan;179(2):337-347. PMID: 31655920
J Pharmacol Sci

2025 Dec 16;160(2):132-141.
Discov Oncol

Aberrant expression of MRAS and HEG1 as the biomarkers for osimertinib resistance in LUAD. [Abstract]

2024 Nov 19;15(1):678. PMID: 39560891
J Cancer Res Clin Oncol

Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance. [Abstract]

2023 Feb;149(2):669-682. PMID: 36401637
Exp Eye Res

Elimination of senescent cells inhibits epithelial-mesenchymal transition of retinal pigment epithelial cells. [Abstract]

2022 Oct:223:109207. PMID: 35926646
Cell Biochem Funct

Targeted inhibition of ACK1 can inhibit the proliferation of hepatocellular carcinoma cells through the PTEN/AKT/mTOR pathway. [Abstract]

2020 Jul;38(5):642-650. PMID: 32162707
PLoS One

A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery. [Abstract]

2024 Nov 1;19(11):e0308647. PMID: 39485774
PLoS One

Validated UPLC-MS/MS method for the quantification of dasatinib in plasma: Application to pharmacokinetic interaction studies with nutraceuticals in Wistar rats. [Abstract]

2018 Jun 14;13(6):e0199208. PMID: 29902246
PLoS One

Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells. [Abstract]

2013;8(2):e56473. PMID: 23437141
J Nat Med

Tenacissoside G reverses paclitaxel resistance by inhibiting Src/PTN/P-gp signaling axis activation in ovarian cancer cells. [Abstract]

2025 Apr 8. PMID: 40195205
Hear Res

Uncovering cellular senescence as a therapeutic target in NF2-related vestibular schwannoma. [Abstract]

2024 Dec 4:455:109165. PMID: 39647233
Behav Brain Res

Combined use of dasatinib and quercetin alleviates overtraining-induced deficits in learning and memory through eliminating senescent cells and reducing apoptotic cells in rat hippocampus. [Abstract]

2023 Feb 25:440:114260. PMID: 36535433
Int J Rheum Dis

Dasatinib, a selective tyrosine kinase inhibitor, prevents joint destruction in rheumatoid arthritis animal model. [Abstract]

2023 Apr;26(4):718-726. PMID: 36808837
Biomed Chromatogr

UPLC-MS/MS study of the effect of dandelion root extract on the plasma levels of the selected irreversible tyrosine kinase inhibitors dasatinib, imatinib and nilotinib in rats: Potential risk of pharmacokinetic interactions. [Abstract]

2019 Dec;33(12):e4674. PMID: 31376170
Biol Pharm Bull

Synergistic Inhibition of Breast Cancer Cell Growth by an Epigenome-Targeting Drug and a Tyrosine Kinase Inhibitor. [Abstract]

2017;40(10):1747-1753. PMID: 28966246

Dasatinib purchased from MedChemExpress. Usage Cited in: Biol Pharm Bull. 2017;40(10):1747-1753. [Abstract]

Synergistic Decrease Bcl-2 Expression by the Combination of SAHA with Dasatinib in MCF-7 Cells.
J Toxicol Sci

Validation of a new protocol for a zebrafish MEFL (malformation or embryo-fetal lethality) test method that conforms to the ICH S5 (R3) guideline. [Abstract]

2024;49(8):337-348. PMID: 39098043
Chem Pharm Bull (Tokyo)

Synergistic Activity of an Antimetabolite Drug and Tyrosine Kinase Inhibitors against Breast Cancer Cells. [Abstract]

2017 Aug 1;65(8):768-775. PMID: 28539531

Dasatinib purchased from MedChemExpress. Usage Cited in: Chem Pharm Bull (Tokyo). 2017 Aug 1;65(8):768-775. [Abstract]

Changes in Bcl-2 protein expression in MCF-7 cells after treatment with NSC 105014, Dasatinib or ZD1839 alone or in combination for 12 h. Expression of Bcl-2 protein is analyzed by western blotting analysis.
Res Sq

2026 Jun 19.
Res Sq

2026 May 6.
bioRxiv

2026 Jan 17.
bioRxiv

2025 Dec 5.
Blood Vessel Thromb Hemost

2025 Nov 17.
bioRxiv

2025 Nov 14.
bioRxiv

2025 Sep 30.
University of Otago

2025 Oct 7.
bioRxiv

2025 Oct 25.
Res Sq

2025 Sep 23.
bioRxiv

2025 Sep 5.
University of New York

2025.
bioRxiv

Post-Translational Modifications Remodel Proteome-Wide Ligandability. [Abstract]

2025 Aug 2:2025.07.31.667978. PMID: 40766426
bioRxiv

Closing the loop: Teaching single-cell foundation models to learn from perturbations. [Abstract]

2025 Jul 12:2025.07.08.663754. PMID: 40672312
bioRxiv

2025 Jun 27.
University of Osaka

2025.
Res Sq

Novel mixed cancer-cell models designed to capture inter-patient tumor heterogeneity for accurate evaluation of drug combinations. [Abstract]

2025 May 16:rs.3.rs-6590535. PMID: 40470249
Research Square Print

2025 May 28.
Res Sq

2025 Apr 14.
bioRxiv

2025 February 26.
bioRxiv

2025 February 18.
Patent

US20240319170A1
Patent

US20240325538A1.
University of Düsseldorf

2024.
bioRxiv

All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer. [Abstract]

2024 Oct 23:2024.10.20.619300. PMID: 39484589
Patent

US20240238271A1.
bioRxiv

Senescent fibroblasts in the tumor stroma rewire lung cancer metabolism and plasticity. [Abstract]

2024 Jul 30:2024.07.29.605645. PMID: 39131266
bioRxiv

2024 July 19.
SSRN

2024 Apr 1.
bioRxiv

2023 Dec 14.
Patent

US20230226111A1.
Int J Pharm Res Allied Sci

2023 Mar;13(1):139-148.
Purdue University

2022.
Patent

US10174018B2.
Patent

US20180263995A1.
Patent

US20180099960A1.
Patent

US20180099961A1.
Patent

US20180099959A1.
Technical University of Munich

24.01.2018.
Kawasaki Medical Journal

43(2)：63-78，2017.

Dasatinib purchased from MedChemExpress. Usage Cited in: Kawasaki Medical Journal. 43(2)：63-78，2017.

Western blot analysis of effects of Dasatinib (10 or 100nM) on c-Src, p-SrcY416, FAK and p-FAKY861 expression levels in KTC-1 cells and band intensities for p-SrcY416.
Oncotarget

The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib. [Abstract]

2016 Aug 30;7(35):56241-56252. PMID: 27494842

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (204.91 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0491 mL

10.2455 mL

20.4910 mL

5 mM

0.4098 mL

2.0491 mL

4.0982 mL

10 mM

0.2049 mL

1.0245 mL

2.0491 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution

Protocol 2

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution

Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 4

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 5

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 50 mg/mL (102.45 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 20% SBE-β-CD in Saline

Solubility: 2 mg/mL (4.10 mM); Suspended solution; Need ultrasonic

Protocol 3

Add each solvent one by one: 0.5% Methyl cellulose/0.5% Tween-80 in Saline water

Solubility: 6.67 mg/mL (13.67 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Lombardo LJ, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004 Dec 30;47(27):6658-61. [Content Brief]

[2]. Porkka K, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008 Aug 15;112(4):1005-12. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0491 mL	10.2455 mL	20.4910 mL	51.2274 mL
	5 mM	0.4098 mL	2.0491 mL	4.0982 mL	10.2455 mL
	10 mM	0.2049 mL	1.0245 mL	2.0491 mL	5.1227 mL
	15 mM	0.1366 mL	0.6830 mL	1.3661 mL	3.4152 mL
	20 mM	0.1025 mL	0.5123 mL	1.0245 mL	2.5614 mL
	25 mM	0.0820 mL	0.4098 mL	0.8196 mL	2.0491 mL
	30 mM	0.0683 mL	0.3415 mL	0.6830 mL	1.7076 mL
	40 mM	0.0512 mL	0.2561 mL	0.5123 mL	1.2807 mL
	50 mM	0.0410 mL	0.2049 mL	0.4098 mL	1.0245 mL
	60 mM	0.0342 mL	0.1708 mL	0.3415 mL	0.8538 mL
	80 mM	0.0256 mL	0.1281 mL	0.2561 mL	0.6403 mL
	100 mM	0.0205 mL	0.1025 mL	0.2049 mL	0.5123 mL

Dasatinib

175 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Dasatinib

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Cytoskeleton Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Targeted Therapy Drug Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Target Protein Ligand Library

Non-steroidal Anti-Inflammatory Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

Posttranslational Modification Library

Nephrotoxicity Compound Library

FDA Kinase Inhibitor Library

RNA Binding Bioactive Compound Library

Classic FDA-Approved Drug Library

Publications Citing Use of MedChemExpress (MCE) Dasatinib

Alle Bcr-Abl Isoform-spezifische Produkte anzeigen

Alle Src Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (175)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Dasatinib Related Classifications

Art. -Nr.: HY-10181